Skip to content

Biomarkers in Islet Cell Transplantation for Type 1 Diabetes

Research output: Contribution to journalReview article

Original languageEnglish
Article number94
JournalCurrent diabetes reports
Volume18
Issue number10
Early online date5 Sep 2018
DOIs
DateAccepted/In press - 4 Sep 2018
DateE-pub ahead of print - 5 Sep 2018
DatePublished (current) - 1 Oct 2018

Abstract

Purpose of Review: Islet transplantation, an important approach to achieve insulin independence for individuals with type 1 diabetes, is limited by the lack of accurate biomarkers to track beta-cell death post islet infusion. In this review, we will discuss existing and recently described biomarkers.

Recent Findings: As beta cells are killed by the immune system, fragments of beta cell-specific cell-free DNA and proteins are released into the periphery. Several different strategies to identify these fragments have been described. Some circulating, non-coding microRNAs, particularly miRNA-375 are also showing potential to reflect the rate of beta cell loss post-clinical islet transplantation.

Summary: Recent advances in identifying accurate beta cell-specific biomarkers such as differentially methylated insulin cell-free DNA and circulating miRNA-375 may help predict clinical outcomes. More studies are required to examine the robustness of these biomarkers to detect chronic beta-cell loss in islet transplantation recipients.

    Research areas

  • Biomarker, Cell-free DNA, Islet transplantation, microRNA 375, Type 1 diabetes

Download statistics

No data available

Documents

Documents

  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Springer at https://doi.org/10.1007/s11892-018-1059-4. Please refer to any applicable terms of use of the publisher.

    Final published version, 656 KB, PDF document

    Licence: CC BY

DOI

View research connections

Related faculties, schools or groups